LEILA SAHNI to Respiratory Syncytial Virus Vaccines
This is a "connection" page, showing publications LEILA SAHNI has written about Respiratory Syncytial Virus Vaccines.
Connection Strength
0.477
-
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 May 08; 74(16):273-281.
Score: 0.222
-
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
Score: 0.204
-
Medical Costs of Respiratory Syncytial Virus-Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5?Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019. J Pediatr. 2024 Aug; 271:114045.
Score: 0.051